Literature DB >> 26844946

6-sulpho LacNAc(+) dendritic cells accumulate in various inflammatory, but not ischaemic conditions of the central nervous system.

K Thomas1, I Metz2, H Tumani3, W Brück2, T Ziemssen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26844946     DOI： 10.1111/nan.12313

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN： 0305-1846            Impact factor:   8.090


× No keyword cloud information.
  4 in total

1.  Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.

Authors:  Tjalf Ziemssen; Hayrettin Tumani; Tony Sehr; Katja Thomas; Friedemann Paul; Nils Richter; Emil Samara; Ofer Spiegelstein; Ella Sorani; Oren Bar-Ilan; Dorit Mimrod; Liat Hayardeny
Journal:  J Neuroinflammation       Date:  2017-08-31       Impact factor: 8.322

2.  Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation.

Authors:  Katja Thomas; Tony Sehr; Undine Proschmann; Francisco Alejandro Rodriguez-Leal; Rocco Haase; Tjalf Ziemssen
Journal:  J Neuroinflammation       Date:  2017-02-23       Impact factor: 8.322

3.  Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.

Authors:  Tjalf Ziemssen; Katja Thomas
Journal:  Ther Adv Neurol Disord       Date:  2017-08-04       Impact factor: 6.570

4.  Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.

Authors:  Z Li; S Richards; H K Surks; A Jacobs; M A Panzara
Journal:  Clin Exp Immunol       Date:  2018-10-01       Impact factor: 4.330
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.